Jan. 29 at 12:46 AM
$ANVS Well, to put things in perspective, just a few days ago clinical stage CRVS was trading at
$6 pps when they announced the results of a phase 1 safety study on an eczema drug showing it to be safe and begining to separate from placebo showing a little improvement after 8 days. The stock soared to
$26 with a MC of
$2 Billion with PT’s raised to
$42-
$46. They immediately had a pre planned stock offering for
$175 million curing their cash shortage. The TAM for CRVS’s drug candidate is not as large as ANVS TAM. ANVS candidate is at a more advanced stage of development with multiple indications and has a FDA endorsed pathway for approval. Yet, the MC of ANVS is only
$80 million. The risk/reward with ANVS drug, which is not only safe, but has been shown to be significantly effective. Plus it’s substantially closer to getting FDA approval. Any number of near term events will radically change the MC & share price for investors who hold a position in the stock.
